MAURICE VOLMEYER / SHUTTERSTOCK.COM
The FDA could approve the US’s first biosimilar product any day now. But is the country ready for the wave of biosimilar applications that will surely follow, and how quickly can these cut-price drugs come to market? LSIPR reports.
In March 2010, US President Barack Obama signed the Patient Protection and Affordable Care Act, also known as Obamacare, into law. It was preceded in 2009 by the Biologics Price Competition and Innovation Act (BPCIA), which introduced a shortened pathway for approving biosimilars, medicines that have been developed to be close to existing biologic drugs.
Last July, the US Food and Drug Administration (FDA) approved for review the US’s first biosimilar application—Sandoz’s Zarzio.
Zarzio is a follow-on version of Amgen’s drug Neupogen (filgrastim), which stimulates the growth of white blood cells in the body, and is used to treat patients who have low levels of white blood cells because of cancer, or have recently undergone a bone marrow transplant.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Biosimilar, Zarzio, BPCIA, FDA, Sandoz, patent, Myriad